Free Trial

Actuate Therapeutics (ACTU) Competitors

Actuate Therapeutics logo
$7.03 +0.04 (+0.53%)
As of 10:24 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ACTU vs. CGEM, KMDA, ERAS, AQST, CMPX, FULC, RGNX, TECX, MBX, and SNDL

Should you be buying Actuate Therapeutics stock or one of its competitors? The main competitors of Actuate Therapeutics include Cullinan Therapeutics (CGEM), Kamada (KMDA), Erasca (ERAS), Aquestive Therapeutics (AQST), Compass Therapeutics (CMPX), Fulcrum Therapeutics (FULC), REGENXBIO (RGNX), Tectonic Therapeutic (TECX), MBX Biosciences (MBX), and SNDL (SNDL). These companies are all part of the "pharmaceutical products" industry.

Actuate Therapeutics vs. Its Competitors

Actuate Therapeutics (NASDAQ:ACTU) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Actuate Therapeutics' return on equity of 0.00% beat Cullinan Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Actuate TherapeuticsN/A N/A -339.73%
Cullinan Therapeutics N/A -29.47%-28.19%

Actuate Therapeutics presently has a consensus price target of $20.50, indicating a potential upside of 191.73%. Cullinan Therapeutics has a consensus price target of $30.00, indicating a potential upside of 266.75%. Given Cullinan Therapeutics' higher probable upside, analysts clearly believe Cullinan Therapeutics is more favorable than Actuate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Actuate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cullinan Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Actuate Therapeutics and Actuate Therapeutics both had 1 articles in the media. Cullinan Therapeutics' average media sentiment score of 1.87 beat Actuate Therapeutics' score of 0.93 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Actuate Therapeutics Positive
Cullinan Therapeutics Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Actuate TherapeuticsN/AN/A-$27.28MN/AN/A
Cullinan TherapeuticsN/AN/A-$167.38M-$2.91-2.81

86.3% of Cullinan Therapeutics shares are held by institutional investors. 69.3% of Actuate Therapeutics shares are held by insiders. Comparatively, 7.2% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Cullinan Therapeutics beats Actuate Therapeutics on 5 of the 8 factors compared between the two stocks.

Get Actuate Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACTU vs. The Competition

MetricActuate TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$137.14M$3.04B$5.71B$9.50B
Dividend YieldN/A2.40%4.60%3.99%
P/E RatioN/A20.8727.8819.97
Price / SalesN/A324.50452.35101.58
Price / CashN/A43.2336.5558.97
Price / Book702.708.328.635.89
Net Income-$27.28M-$55.19M$3.24B$258.50M
7 Day Performance22.00%5.61%3.90%2.07%
1 Month Performance9.11%17.39%10.47%12.39%
1 Year PerformanceN/A4.47%34.29%19.25%

Actuate Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACTU
Actuate Therapeutics
2.275 of 5 stars
$7.03
+0.5%
$20.50
+191.7%
N/A$137.14MN/A0.0010
CGEM
Cullinan Therapeutics
2.0948 of 5 stars
$7.52
-0.1%
$30.00
+298.9%
-59.0%$444.38MN/A-2.5830Positive News
KMDA
Kamada
3.8821 of 5 stars
$7.80
+4.7%
$13.00
+66.7%
+33.7%$428.41M$160.95M26.90360News Coverage
Positive News
ERAS
Erasca
2.1991 of 5 stars
$1.50
flat
$4.57
+204.8%
-45.0%$424.93MN/A-2.42120Positive News
AQST
Aquestive Therapeutics
1.7526 of 5 stars
$4.23
+0.7%
$10.14
+139.8%
+24.6%$417.18M$57.56M-7.17160Positive News
CMPX
Compass Therapeutics
3.0659 of 5 stars
$3.07
+2.3%
$12.67
+312.6%
+230.9%$414.85M$850K-7.4920Positive News
FULC
Fulcrum Therapeutics
0.5432 of 5 stars
$7.10
-7.2%
$6.29
-11.5%
-8.6%$412.94M$80M-101.41100Upcoming Earnings
RGNX
REGENXBIO
4.1707 of 5 stars
$8.49
+4.0%
$31.63
+272.5%
-33.1%$409.31M$156.72M-2.73370News Coverage
Positive News
TECX
Tectonic Therapeutic
2.7096 of 5 stars
$21.92
+0.0%
$80.33
+266.5%
+31.1%$409.11MN/A-3.00120
MBX
MBX Biosciences
2.2262 of 5 stars
$12.19
+3.7%
$37.57
+208.2%
N/A$407.44MN/A0.0036
SNDL
SNDL
1.9349 of 5 stars
$1.58
+2.6%
$4.00
+153.2%
-30.8%$404.67M$671.81M-5.452,516News Coverage
Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:ACTU) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners